Trial Profile
Influence of CYP2C19 genetic variants on clopidogrel in healthy subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Clopidogrel (Primary)
- Indications Acute coronary syndromes; Embolism and thrombosis; Myocardial infarction; Peripheral arterial occlusive disorders; Stroke
- Focus Pharmacodynamics; Pharmacogenomic
- Acronyms CLOVIS
- 05 Jul 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 07 May 2011 Planned number of patients changed from 30 to 140.
- 16 Jul 2007 Status change from initiated to recruiting